Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

PRIMARY OBJECTIVES: I. To determine the safety, tolerability and maximum tolerated dose (MTD) of sorafenib, when administered in combination with SRS to patients with 1-4 metastatic brain tumors. SECONDARY OBJECTIVES: I. To assess the six-month intra-cranial progression-free survival (PFS) of sorafenib when administered in combination with SRS to patients with 1-4 metastatic brain tumors. PFS is defined as the time to intra-cranial tumor progression or death. II. To assess the six-month overall survival (OS) of sorafenib when administered in combination with SRS to patients with 1-4 metastatic brain tumors. III. To compare results to patients who are treated with SRS alone (concurrent controls). OUTLINE: This is a dose-escalation study of sorafenib tosylate. Patients receive oral (PO) sorafenib tosylate once daily and undergo SRS 5-7 days later. Treatment with sorafenib continues for 2 weeks after SRS in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 8, 26, and 52 weeks.